Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03915184 · ClinicalTrials.gov registry record · Phase 1
Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)
A Phase 1 study of Multiple Myeloma, sponsored by CARsgen Therapeutics Co..
- Active
- Registry status
- Phase 1
- Development phase
- 105
- Enrollment target
- 13
- Study locations
NCT03915184: Active Phase 1 study of Multiple Myeloma, sponsored by CARsgen Therapeutics Co..
NCT03915184 is a Phase 1 study of Multiple Myeloma that is active but no longer recruiting, run by CARsgen Therapeutics Co.. The registered enrollment target is 105 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (81% lower). The trial reports 13 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03915184, a Phase 1 study of Multiple Myeloma, is active but no longer recruiting, sponsored by CARsgen Therapeutics Co..
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 105 participants
- Enrollment target
- 13
- Study locations
Study Summary
A phase 1b/2, open label, multi-center, Clinical Study of Chimeric Antigen Receptor T Cells targeting BCMA in patients with relapsed and or refractory multiple myeloma.
Primary Outcome
Incidence of Treatment Related AEs, AEs of special interest and serious adverse events (SAEs)
Conditions Studied
Interventions
- BIOLOGICAL zevor-cel
Study Locations (13)
Texas
- UT Southwestern Medical Center - Dallas
- MD Anderson - Houston
- Methodist Hosptial - Houston
Arizona
- Mayo Clinic Hospital - Phoenix
California
- UCSF - San Francisco
Colorado
- Colorado Blood Cancer Institute - Denver
Florida
- Moffitt Cancer Center - Tampa
Massachusetts
- Dana Farber Cancer Center - Boston
Minnesota
- Mayo - Rochester
Tennessee
- TriStar CMC - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2019-09-25 |
| Est. Completion | 2034-12-31 |
| Phase | Phase 1 |
What the registry record for NCT03915184 still lists
NCT03915184 is an interventional study that assigns participants to a tested intervention. The registered 105 participants enrollment target is mid-sized for trials with a published cap, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which zevor-cel is the first listed.
NCT03915184 lists 13 locations in 11 states (Texas, Arizona, California).
Frequently Asked Questions
What is clinical trial NCT03915184 about?
NCT03915184 is a clinical study titled "Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)". A phase 1b/2, open label, multi-center, Clinical Study of Chimeric Antigen Receptor T Cells targeting BCMA in patients with relapsed and or refractory multiple myeloma.
What is the current status of trial NCT03915184?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 105 participants. The study started on 2019-09-25. Estimated completion is 2034-12-31.
What conditions does trial NCT03915184 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT03915184?
The interventions under investigation include: zevor-cel (BIOLOGICAL).
Who is sponsoring clinical trial NCT03915184?
This trial is sponsored by CARsgen Therapeutics Co., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03915184 being conducted?
This trial has 13 study locations across Arizona, California, Colorado, Florida, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03915184's enrollment target sits among peer trials
105 162nd of 438 higher than 277 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03372317 · 105 participants
Tau PET in Imaging and Cognition: Healthy Adults From 55-90
- NCT04253964 · 105 participants · Phase 2
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
- NCT04742452 · 105 participants · NA
Comparison of Partial Rotator Cuff Repair vs. Superior Capsular Reconstruction for Irreparable Rotator Cuff Tears
- NCT04875429 · 105 participants · NA
Zenith® Fenestrated+ Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI